title: Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis.
abstract: To determine the potential toxicity of prolonged aerosol tobramycin administration, 22 patients with cystic fibrosis were monitored while receiving inhaled tobramycin three times a day for 12 weeks. Prior to, four times during administration and approximately 6 weeks after discontinuation of treatment, we assessed pulmonary function, weight, height, body temperature, eighth cranial nerve function, serum creatinine, blood urea nitrogen, urinary creatinine clearance, plasma iothalamate clearance, urinary beta-2 microglobulin concentration, and Pseudomonas aeruginosa density in sputum. There was no detectable laboratory evidence of nephrotoxicity. Neither a decrease in auditory acuity (range 250-20,000 Hz) nor vestibular dysfunction was detected. Pulmonary function tests significantly improved during the first month in all subjects (P less than 0.05) but returned to enrollment values by the end of the 12th week of administration of tobramycin aerosol. Sputum P. aeruginosa density initially decreased from a mean of 10(7) cfu/gm to a mean of 10(4) cfu/gm after 2 weeks of aerosol tobramycin administration and remained significantly below the enrollment value throughout. Coincident with the reduced bacterial density, a reduction in cough frequency and sputum production, as well as a weight gain was observed. Seventy-three percent of the patients with sputum P. aeruginosa isolates susceptible to tobramycin on enrollment yielded resistant organisms during aerosol administration. However, 1 year later all sputum P. aeruginosa isolates obtained from patients were susceptible to tobramycin. We conclude that thrice daily aerosol tobramycin administration for 3 months is not associated with detectable eighth cranial nerve or renal toxicity. Transient emergence of tobramycin resistant P. aeruginosa may occur.
authors.affiliation: Department of Pediatrics, University of Washington School of Medicine, Seattle.
authors.forename: A L
authors.initials: AL
authors.lastname: Smith
authors.forename: B W
authors.initials: BW
authors.lastname: Ramsey
authors.forename: D L
authors.initials: DL
authors.lastname: Hedges
authors.forename: B
authors.initials: B
authors.lastname: Hack
authors.forename: J
authors.initials: J
authors.lastname: Williams-Warren
authors.forename: A
authors.initials: A
authors.lastname: Weber
authors.forename: E J
authors.initials: EJ
authors.lastname: Gore
authors.forename: G J
authors.initials: GJ
authors.lastname: Redding
mesh_terms: D000280:Administration, Inhalation; D000336:Aerosols; D002648:Child; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications* / Q000188:drug therapy; D004352:Drug Resistance, Microbial; D006801:Humans; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D012129:Respiratory Function Tests; D013183:Sputum / Q000032:analysis / Q000382:microbiology; D013997:Time Factors; D014031:Tobramycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000032:analysis
chemical_list: D000336:Aerosols; D014031:Tobramycin